Satisfaction in older patients by geriatric assessment using a novel tablet-based questionnaire system: A cluster-randomized, phase III trial of patients with non-small-cell lung cancer (ENSURE-GA study; NEJ041/CS-Lung001)

被引：0

作者：

Soda, Sayo

Mirokuji, Kie

Saito, Ryota

Takamura, Kei

Morita, Ryo

Furuya, Naoki

Kuyama, Shoichi

Shiono, Ayako

Arai, Daisuke

Hosokawa, Shinobu

Masubuchi, Ken

Matsumoto, Naoko

Asahina, Hajime

Kondo, Haruka

Honda, Ryoichi

Hattori, Noboru

Yokoyama, Akihito

Kobayashi, Kunihiko

Isobe, Takeshi

Tsubata, Yukari

机构：

[1] Dokkyo Med Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan

[2] Tokyo Metropolitan Komagome Hosp, Dept Resp Med, Tokyo, Japan

[3] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan

[4] Obihiro Kosei Gen Hosp, Dept Internal Med 1, Obihiro, Hokkaido, Japan

[5] Akita Kousei Med Ctr, Dept Resp Med, Akita, Japan

[6] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan

[7] Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan

[8] Saitama Med Univ Int Med Ctr, Dept Resp Med, Saitama, Japan

[9] Saiseikai Utsunomiya Hosp, Dept Pulm Med, Utsunomiya, Tochigi, Japan

[10] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan

[11] Gunma Prefectural Canc Ctr, Dept Pulm Med, Ohta, Gumma, Japan

[12] Hiroshima Red Cross Hosp Hiroshima, Dept Resp Internal Med, Hiroshima, Japan

[13] Atom Bomb Survivors Hosp, Hiroshima, Japan

[14] Hokkaido Univ, Grad Sch Med, Dept Resp Med, Sapporo, Japan

[15] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan

[16] Asahi Gen Hosp, Dept Resp Med, Asahi, Japan

[17] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[18] Kochi Univ, Kochi Med Sch, Dept Resp Med & Allergol, Kochi, Japan

[19] Saitama Med Univ Int Med Ctr, Dept Resp Med, Saitama, Japan

[20] Shimane Univ, Fac Med, Dept Internal Med, Div Med Oncol & Resp Med, Izumo, Shimane, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

12041

引用

页数：1

共 26 条

[21] Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
Spigel, David R.
Edelman, Martin J.
Mok, Tony
O'Byrne, Kenneth
Paz-Ares, Luis
Yu, Wei
Rittweger, Karen
Thurm, Holger
CLINICAL LUNG CANCER, 2012, 13 (06) : 500 - 504
[22] Antiemetic efficacy of casopitant, a novel NK-1 receptor antagonist, in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy: subgroup analysis from a randomized, double-blind, placebo-controlled phase III trial
Grunberg, Steven M.
Lane, Stephen R.
Wissel, Paul S.
Russo, Mark W.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S368 - S368
[23] Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
Goldman, Jonathan W.
Shi, Peipei
Reck, Martin
Paz-Ares, Luis
Koustenis, Andrew
Hurt, Karla C.
CLINICAL LUNG CANCER, 2016, 17 (01) : 80 - 84
[24] An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial
Gelsomino, F.
Tiseo, M.
Boni, L.
Cavanna, L.
Camerini, A.
Chiari, R.
Verusio, C.
Tognetto, M.
Ardizzoni, A.
ANNALS OF ONCOLOGY, 2019, 30
[25] An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
Gelsomino, Francesco
Boni, Luca
Tiseo, Marcello
Ricciardi, Serena
Rocco, Danilo
Cortinovis, Diego L.
Proietto, Manuela
Cogoni, Alessio
Pasello, Giulia
Camerini, Andrea
Sperandi, Francesca
Colantonio, Ida
Metro, Giulio
Mazzoni, Francesca
Baldini, Editta
Veccia, Antonello
Bennicelli, Elisa
Bettini, Anna Cecilia
Tognetto, Michele
LUNG CANCER, 2025, 199
[26] PHASE III, RANDOMIZED, MULTICENTER STUDY COMPARING IN ELDERLY PATIENTS (≥70 YEARS) WITH STAGE IV NON SMALL-CELL LUNG CANCER (NSCLC) A STANDARD STRATEGY OF TREATMENT ALLOCATION (CARBOPLATIN BASED BI-THERAPY OR MONOTHERAPY WITH DOCETAXEL) BASED ON PERFORMANCE STATUS (PS) AND AGE WITH AN EXPERIMENTAL STRATEGY ALLOCATING THE SAME CHEMOTHERAPIES OR BEST SUPPORTIVE CARE (BSC) ACCORDING TO A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) - STUDY ESOGIA-GFPC-GECP 08-02
Corre, Romain
Chouaid, Christos
Greillier, Laurent
Le Caer, Herve
Audigier-Valette, Clarisse
Baize, Nathalie
Berard, Henry
Falchero, Lionel
Monnet, Isabelle
Dansin, Eric
Vergnenegre, Alain
Marcq, Marie
Decroistte, Chantal
Bota, Suzanna
Lamy, Regine
Massuti, Bartomeu
Dujon, Cecile
Fraboulet, Ghislaine
Minguet, Johanna
Plassot, Carine
Lena, Herve
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S192 - S193

← 1 2 3 →